Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    FDA Approves Synthetic Conjugated Oestrogens-A Vaginal Cream for Vulvar, Vaginal Atrophy Symptoms - (DGNews)
    Cetuximab Approved for First-Line Treatment of Head and Neck Cancer in Europe - (DGNews)
    Stromal Gene Signatures in Large-B-Cell Lymphomas - (N Engl J Med)
    Variations in Gene Activity Can Predict the Survival of Patients With Lymphoma - (DGNews)
    Inhaled Corticosteroids in Patients With Stable Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis - (JAMA)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
      Diabetes: Treatment of Type 2 Diabetes and the Role of Insulin
      Cases in Cardiology: Complications Associated with Heparin Therapy
      Aggressive Management of Type 2 Diabetes to Prevent Macrovascular Complications
      Asthma Treatment Guidelines and Use of Inhalers
      Use of Probiotics in the Management of Antibiotic-associated Diarrhea

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Experience with Adjuvant Chemotherapy for Pseudomyxoma Peritonei Secondary to Mucinous Adenocarcinoma of the Appendix with Oxaliplatin / Fluorouracil /Leucovorin (FOLFOX4)
        Recognition and Treatment of Serotonin Syndrome
        Is Enoxaparin Injection from the Abdominal Wall Safe in Elderly People?: A Fatal Case of Rectus Sheath Hematoma
        Adalimumab Induced Mononeuritis Multiplex in a Patient with Refractory Rheumatoid Arthritis: A Case Report
        Massive Pulmonary Emboli Associated with Olanzapine

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Smoking-Related Anti-psychotic Dose Adjustment Could Improve Response

        A DGReview of :"The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement"
        Pharmacogenetics

        03/10/2003
        By David Loshak


        Dose adjustment of the atypical anti-psychotic drug clozapine, based on smoking behaviour, would help to counter inadequate antipsychotic response or lower intoxication.

        Researchers in Harderwijk and Ermelo, the Netherlands, reported that clearance of clozapine and daily dose requirement were strongly associated with smoking behaviour, but a related genetic polymorphism seemed to have no significant clinical effect.

        Clozapine was largely metabolised by the cytochrome P450 enzyme CYP1A2. Smoking powerfully induced this enzyme's activity, causing significantly lower clozapine serum concentrations with a given dose in smokers than in non-smokers, the researchers said. They also noted that a single nucleotide polymorphism identified at position 734 of the gene had recently been reported to affect the enzyme's inducibility.

        Because this polymorphism in relation to smoking behaviour might be relevant to treatment with clozapine, the researchers studied the effect of genotype on clozapine clearance and dose requirement in 80 smoking and non-smoking schizophrenic patients receiving clozapine long-term.

        Clozapine serum concentrations were determined by high-performance liquid chromatography and genotype by polymerase chain reaction analysis.

        In smokers, the clozapine serum concentration corrected for dose was 2.5 times lower on average than in non-smokers, indicating enhanced clearance.

        The mean required maintenance doses of clozapine for smokers was 382 mg/day and for non-smokers 197 mg/day.

        Mean corrected-for-dose ratios and daily doses did not significantly vary between patients with the different genotypes in smokers or non-smokers.
        Pharmacogenetics 2003;13:3:169-172. "The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send